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Background: Psoriasis is a chronic autoimmune disease in which T cells have a predominant role in initiating and
perpetuating the chronic inflammation in skin. However, the mechanisms that regulate T cell activation in psoriasis
are still incompletely understood. The objective of the present study was to characterize the main genetic
pathways associated with T cell activation in psoriasis.
Results: Gene expression profiles from in vitro activated T cells were obtained from 17 psoriasis patients and 7
healthy controls using Illumina HT-12 v4 microarrays. From a total of 47,321 analyzed transcripts, 42 genes were
found to be differentially expressed between psoriasis and controls (FDR p-value < 0.1, absolute fold-change > 1.2).
Using an independent cohort of 8 patients and 8 healthy controls we validated the overexpression of SPATS2L
(p-value =0.0009) and KLF6 (p-value =0.0012) genes in activated T cells from psoriasis patients. Using weighted
correlation analysis we identified SPATS2L and KLF6 coexpression networks, which were also significantly associated
with psoriasis (p-value < 0.05). Gene Ontology analysis allowed the identification of several biological processes
associated with each coexpression network. Finally, using Gene Set Enrichment Analysis over the global T cell
transcriptome we also found additional genetic pathways strongly associated with psoriasis (p-value < 0.0001).
Conclusions: This study has identified two new genes, SPATS2L and KLF6, strongly associated with T cell activation
in psoriasis. Functional analyses of the gene expression profiles also revealed new biological processes and genetic
pathways associated with psoriasis. The results of this study provide an important insight into the biology of this
common chronic inflammatory disease.
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Psoriasis is a chronic T-cell-mediated inflammatory dis-
ease that affects approximately 2% of the world popula-
tion [1]. Histologically, it is characterized by the
infiltration of active immune cells into the skin, the
hyperplasia of blood vessels and the hyperproliferation
of keratinocytes. The leukocyte infiltrate in psoriasis le-
sions is composed mainly by T cells, predominantly
CD4 + -type cells but also CD8 + -type T cells [2]. T cells
are known to expand and migrate into the epidermis* Correspondence: sara.marsal@vhir.org
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reproduction in any medium, provided the orbefore the onset of the first epidermal changes, and
steadily continue to do so, promoting and perpetuating
the disease [3].
The central role of T cells in psoriasis pathogenesis
was first evidenced in the late 70s, when the T cell sup-
pressor cyclosporine A was discovered as an effective
treatment for psoriasis inflammation [4]. In the 90′s ele-
gant studies using skin xenografts of with non-lesional
skin from patients with psoriasis showed the conversion
to psoriatic plaques when mice were injected with preac-
tivated T cells from the same patient [5]. Since then, a
substantial amount evidence supporting the key role for
T cells, mainly type 1 T helper subtype (Th1), has been
accumulated [6-11]. More recently, IL17 and IL22td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have been characterized as critical mediators of psoriasis
pathogenesis [12-14]. However, the triggering events and
deregulated pathways that lead to the aberrant T cell ac-
tivation in psoriasis patients are still poorly defined. In
the present study we aimed to increase the knowledge
on this particular aspect of psoriasis etiology by charac-
terizing the T cell gene expression profile associated with
psoriasis during T cell activation.
To date, psoriasis has been investigated by a number
of whole genome gene expression studies. These have
been mainly conducted with skin biopsy samples,
through the comparison of lesional and non-lesional
skin. Gene expression analysis in biopsies from skin le-
sions is of great interest in psoriasis and has produced
several important findings [15-21]. However, one limita-
tion of this approach is that the mixture of the different
cell types that coexist in the skin tissue is likely to mask
relevant gene expression patterns. Specially, if the cell
type of interest is not the predominant component of
the total tissue extract, as in the case of infiltrating T
cells in lesional skin, the resulting gene expression data
could not be informative.
An alternative to skin biopsy analysis has been the
analysis of gene expression profiles of peripheral blood
mononuclear cells (PBMCs) from patients and controls
[22-25]. This approach is of particularly interest in
immune-mediated diseases like psoriasis, since it is a less
invasive approach and, consequently, predictive profiles
can have a better translation into the clinical setting.
However, most T cells circulating in the peripheral blood
are in a quiescent state [26], with scarce gene expression
activity [27]. Consequently, relevant pathogenic pro-
cesses like T cell activation might not well be studied
through this approach.
In the present study we have used in vitro activated T
cells from patients and healthy controls to characterize
the gene expression profile associated with psoriasis.
Using an independent cohort of patients and controls
we have validated the most significant genes associated
with this differential regulatory activity. Finally, using
different genomic approaches we have characterized the
gene expression networks and biological pathways that
characterize this key aspect of psoriasis biology.
Results
Gene expression profiles from in vitro activated T cells
were obtained from 17 psoriasis patients and 7 healthy
controls using Illumina HT-12 v4 microarrays. From
each individual gender, age was collected, and Psoriasis
Area and Severity Index (PASI) score was determined
for each patient at the time of sample collection
(Additional file 1). There were no statistically significant
differences (P > 0.05) in age or gender between themicroarray and validation case control samples. Also,
the PASI score was not significantly different between
discovery and validation patient samples. From each
RNA sample, a total of 47,321 transcripts were quanti-
fied and 23,554 probes were called as expressed in the
sample (i.e. present in 2 or more individuals) according
to the Illumina expression score and selected for statis-
tical analysis.
Differentially expressed genes in in vitro activated T cells
A total of 42 genes were found to be significantly associ-
ated with psoriasis (FDR p-value < 0.1, absolute fold
change > 1.2, Additional file 2). From these, 25 were
found to be up-regulated in T cells from psoriasis pa-
tients and 17 genes were down-regulated in patients
compared to controls. The genes with FDR p-value <
0.05 showing the largest change in gene expression
(i.e. absolute fold change > 1.2) are shown in Table 1.
Validation of genes associated with psoriasis in T cells
From the list of significant differentially expressed genes,
we selected those genes showing a high level of statis-
tical association (Pcorrected < 0.005) with the largest ab-
solute change in expression (i.e. Fold Change (FC) > 1.3)
for validation. These genes were spermatogenesis associ-
ated serine-rich 2-like (SPATS2L, FC = 1.37, Pcorrected =
0.0009), Kruppel-like factor 6 (KLF6, FC = 1.32, p-value =
0.0012), SP140 nuclear body protein (SP140, FC = 1.38,
p-value = 0.0025) and RAR-related orphan receptor A
(RORA, FC = 1.31, p-value = 0.0041) (Figure 1a) genes.
Using the same set of samples from the microarray ana-
lysis we first performed a RT-PCR technical validation
study. We were able to validate the differential expres-
sion observed for SPATS2L (FC = 1.39, p-value =
0.0006), KLF6 (FC = 1.24, p-value = 0.022) and SP140
(FC = 1.34, p-value = 0.019) genes (Figure 1b). RORA
differential expression was not validated (p-value > 0.05)
and, consequently, we did not perform biological valid-
ation on this sample.
After technical validation, we used an independent
sample of patients and controls recruited from the same
University Hospitals to validate the association of
SPATS2L, KLF6 and SP140 genes with the activation of
T cells in psoriasis. Using in vitro activated T cells from
8 patients and 8 controls we significantly validated the
overexpression of SPATS2L (FC = 1.58, p-value = 0.0014)
and KLF6 (FC = 1.23, p-value = 0.024) genes in psoriasis
(Figure 1b). SP140 did not show significant differential
expression in the independent replication cohort.
Identification of SPAT2SL and KLF6 coexpression
networks
Since SPAT2SL and KLF6 have not been previously asso-
ciated to the T lymphocyte activation process, we aimed
Table 1 List of most significantly up-regulated genes in in vitro activated T cells of psoriasis patients compared to
healthy controls
Probe Gene Fold change P value* Full name
Upregulated genes
ILMN_1683678 SPATS2L 1.37 0.0009 Spermatogenesis associated, serine-rich 2-like
ILMN_1735014 KLF6 1.32 0.0012 Kruppel-like factor 6
ILMN_1703263 SP140 1.38 0.0025 SP140 nuclear body protein
ILMN_2322498 RORA 1.31 0.0041 RAR-related orphan receptor A
ILMN_2246956 BCL2 1.23 0.0062 B-cell CLL/lymphoma 2
ILMN_2397721 GLB1 1.23 0.0062 Galactosidase, beta 1
ILMN_1781285 DUSP1 1.21 0.0071 Dual specificity phosphatase 1
ILMN_2321064 BAX 1.24 0.0096 BCL2-associated X protein
ILMN_1731107 CCDC92 1.33 0.0136 Coiled-coil domain containing 92
ILMN_1729749 HERC5 1.72 0.0267 Hect domain and RLD 5
ILMN_2095660 TMEM156 1.29 0.0453 Transmembrane protein 156
ILMN_1681301 AIM2 1.42 0.0464 Absent in melanoma 2
ILMN_1767470 SCPEP1 1.26 0.0469 Serine carboxypeptidase 1
Downregulated genes
ILMN_1778617 TAF9 −1.25 0.0009 TAF9 RNA polymerase II, TATA box binding protein
(TBP)-associated factor, 32kDa
ILMN_2143250 FAR1 −1.20 0.0207 Fatty acyl CoA reductase 1
ILMN_1720114 GMNN −1.20 0.0269 Geminin
ILMN_2135175 SNORD36A −1.27 0.0303 Small nucleolar RNA, C/D box 36A
*Multiple-test corrected p-value.
List of genes with multiple-test corrected p-value < 0.05 and absolute change >1.2. Genes are classified into up-regulated or down-regulated groups and sorted by
their statistical significance. Genes that were selected to validate are highlighted in bold.
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sociated to each of the two genes. For this objective we
used the weighted correlation analysis implemented in
the WGCNA method [28]. After filtering for the most
informative genes (i.e. coefficient of variation > 0.1, n =
4,512 genes), we identified a total of 20 different gene
expression modules (Additional file 3). Using the eigen-
vectors derived from each gene expression module we
evaluated the association to different clinical and epi-
demiological variables (Additional file 4). From these, we
found four modules significantly associated with the
presence of psoriasis (p-value < 0.05, Additional files 5
and 6). These four modules were not associated with
any of the other tested covariates. The first of these
modules (M1, p-value = 0.00051) included 54 genes and
was the most enriched in genes differentially expressed
between psoriasis cases and controls (59.3% at nominal
p-value < 0.05). The second module (M2, p-value =
0.0038) consisted in 92 genes from which 37% were dif-
ferentially expressed. The third module (M3, p-value =
0.011) included 31 genes and 29% from them showed
differential expression. Finally, the fourth module (M4,
p-value = 0.047) included a total of 115 genes, but with a
lower percentage showing differential expression be-
tween cases and controls (24.3%).SPATS2L was found to belong to M1 gene expression
module, while KLF6 was found to be coexpressed with
genes in module M2. The fourth module associated with
psoriasis, M4, included the genome-wide significant RORA
gene that could not be technically validated by RTPCR.
Gene Ontology analyses of SPATS2L and KLF6
coexpression networks
In order to functionally characterize SPATS2L and KLF6
coexpression networks we performed Gene Ontology
(GO) enrichment analysis using DAVID functional an-
notation tool [29]. Table 2 shows the most significantly
enriched GO terms related to biological processes. The
complete list, with the significant GO terms associated
to cellular component and molecular function, is pro-
vided in the Additional file 7.
In the SPATS2L coexpression network, eight GO terms
were found to be significantly enriched (p-values from
0.01 to 0.05). Most of these GO terms were related to dif-
ferent aspects of chromosome and ribosomal biology (e.g.,
GO:0051276, chromosome organization, p-value = 0.019;
GO:0042273, ribosomal biogenesis, p-value = 0.021).
In the KLF6 coexpression network 35 GO terms were
found to be significantly enriched (p-values ranging from
3.95×10e-6 to 0.05). In this network, the most significantly
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Figure 1 Validation of the most significantly up-regulated genes in in vitro activated T cells of psoriasis patients compared to healthy
controls. (a) Heat map of microarray expression data for the genes most significantly associated with psoriasis (FDR p-value < 00.5, FCH > 1.2).
The gene expression values for each gene have been scaled using the minimum and maximum values in order to represent a normalized gene
expression gradient (b) Technical validation of SPATS2L, KLF6, SP140 and RORA genes by RT-PCR (Psoriasis n = 17, and Controls n = 7). (c) Biological
validation of SPATS2L, KLF6 and SP140 genes by RT-PCR in an independent cohort of psoriasis patients and healthy controls (n = 8 each).
**p < 0.01 and *p < 0.05.
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synthesis (n = 7 ontologies), followed by GO terms associ-
ated with amino acid biosynthesis (n = 6 ontologies),
hydrogen sulphide process (n = 2 ontologies) and endo-
plasmic reticulum stress (n = 1 ontology).
Gene set enrichment analysis of the T cell transcriptome
In order to further investigate the biological basis of the
gene expression differences observed between T cells
from psoriasis patients and controls, we analyzed the
global transcriptome using the GSEA approach [30,31].A total of 55 gene sets were found to be significantly
enriched between cases and controls (False Discovery
Rate, FDR < 0.05) (Table 3). From these, four gene sets
were significant at a FDR < 0.0001 all belonging to Reac-
tome database [32] pathway definitions: Cytokine Signal-
ing in Immune System, Interferon Signaling, Interferon
Gamma Signaling and Interferon Alpha/Beta Signaling.
The top gene sets identified using GSEA encoded for
cytokine signalling-related genes, more specifically, for
genes associated with alpha/beta and gamma interferon
signalling. Consistent with this strong interferon response,
Table 2 Summary of the enriched GO Biological Process terms in SPATS2L and KLF6 coexpression networks
Biological process in SPATS2L network
Term Count % p-value
GO:0051276 ~ chromosome organization 5 12.8 1.90E-02
GO:0042273 ~ ribosomal large subunit biogenesis 2 5.1 2.12E-02
GO:0006461 ~ protein complex assembly 5 12.8 2.17E-02
GO:0070271 ~ protein complex biogenesis 5 12.8 2.17E-02
GO:0042254 ~ ribosome biogenesis 3 7.7 2.79E-02
GO:0034622 ~ cellular macromolecular complex assembly 4 10.3 2.99E-02
GO:0034621 ~ cellular macromolecular complex subunit organization 4 10.3 4.01E-02
GO:0006325 ~ chromatin organization 4 10.3 4.63E-02
Biological process in KLF6 network
Term Count % p-value
GO:0006695 ~ cholesterol biosynthetic process 5 6.33 3.95E-06
GO:0016126 ~ sterol biosynthetic process 5 6.33 1.35E-05
GO:0044271 ~ nitrogen compound biosynthetic process 8 10.13 4.08E-04
GO:0006694 ~ steroid biosynthetic process 5 6.33 4.45E-04
GO:0008203 ~ cholesterol metabolic process 5 6.33 6.01E-04
GO:0016125 ~ sterol metabolic process 5 6.33 8.54E-04
GO:0009070 ~ serine family amino acid biosynthetic process 3 3.80 9.36E-04
GO:0008652 ~ cellular amino acid biosynthetic process 4 5.06 1.28E-03
GO:0008610 ~ lipid biosynthetic process 7 8.86 2.30E-03
GO:0008299 ~ isoprenoid biosynthetic process 3 3.80 3.16E-03
GO:0009309 ~ amine biosynthetic process 4 5.06 4.80E-03
GO:0006094 ~ gluconeogenesis 3 3.80 4.92E-03
GO:0009069 ~ serine family amino acid metabolic process 3 3.80 5.31E-03
GO:0019319 ~ hexose biosynthetic process 3 3.80 7.50E-03
GO:0070814 ~ hydrogen sulfide biosynthetic process 2 2.53 8.41E-03
GO:0070813 ~ hydrogen sulfide metabolic process 2 2.53 8.41E-03
GO:0019344 ~ cysteine biosynthetic process 2 2.53 8.41E-03
GO:0034976 ~ response to endoplasmic reticulum stress 3 3.80 8.97E-03
List of enriched GO terms related to biological process (BP) in the SPATS2L (p-value < 0.05) and KLF6 coexpression networks (p-value < 0.01). For each term, the
number of genes present in the network (count), the percentage of enrichment (%) and the associated p-value are indicated.
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(FDR = 0.0014) and RIG and NOD-like receptor pathways
(FDR = 0.0005 and 0.0058, respectively) were also among
the most significantly enriched.
T cell activation in psoriasis patients also resulted in a
significant enrichment of genes involved in PPARα-
mediated activation of gene expression (FDR = 0.0043)
and cholesterol biosynthesis (FDR = 0.0063). Cholesterol
biosynthesis was also the most significant GO biological
process associated with KLF6 coexpression network. Fi-
nally, protein misfolding in the endoplasmic reticulm
was also a common pathway detected by GSEA (i.e. un-
folded protein response, FDR = 0.012) and in the GO
analysis of KLF6 network.Discussion
It is widely accepted that psoriasis is a T-cell mediated
disease, in which lymphocytes continuously infiltrate the
skin promoting and perpetuating inflammation. How-
ever, little is known yet on the gene expression regula-
tion that characterizes T cell activation in psoriasis.
Most of the whole genome gene expression studies in
psoriasis performed to date have been principally been
conducted in skin, where the T cell-associated gene ex-
pression is obscured by other more predominant cell
types like hyperproliferative keratinocytes. Alternatively,
in gene expression studies using freshly isolated blood
lymphocytes, most T cells are found in a quiescent state
and might not reflect gene expression profiles relevant
Table 3 Summary of the GSEA-identified gene sets in in vitro activated T cells of psoriasis patients compared to
healthy controls
Name NES NOM p-val FDR q-val
General processes of immune system
Reactome cytokine signaling in immune system 2.498 0.000 0.0000
KEGG cytokine cytokine receptor interaction 1.980 0.000 0.0130
KEGG hematopoietic cell lineage 1.917 0.000 0.0167
KEGG cell adhesion molecules cams 1.903 0.000 0.0173
Infectious and autoimmune diseases
KEGG autoimmune thyroid disease 1.996 0.002 0.0126
KEGG allograft rejection 1.866 0.000 0.0234
KEGG leishmania infection 1.961 0.000 0.0121
KEGG viral myocarditis 1.900 0.000 0.0175
T cell activation
Reactome downstream TCR signaling 1.869 0.000 0.0232
PID NFAT TF pathway 1.903 0.000 0.0179
PID AP1 pathway 1.936 0.000 0.0148
Biocarta CTLA4 pathway 1.854 0.000 0.0253
Innate immune system activation
Reactome innate immune system 2.145 0.000 0.0014
Reactome inflammasomes 1.905 0.000 0.0180
Reactome antiviral mechanism by IFN stimulated genes 1.915 0.000 0.0160
Reactome RIG I MDA5 mediated induction of IFN alpha beta pathways 2.212 0.000 0.0005
KEGG RIG I like receptor signaling pathway 2.144 0.000 0.0012
Reactome negative regulators of RIG I MDA5 signaling 2.123 0.000 0.0018
KEGG NOD like receptor signaling pathway 1.953 0.000 0.0128
Reactome nucleotide binding domain leucine rich repeat containing receptor NLR signaling pathways 2.048 0.000 0.0058
KEGG toll like receptor signaling pathway 1.802 0.000 0.0398
Reactome TRAF6 mediated IRF7 activation 1.875 0.002 0.0226
KEGG cytosolic DNA sensing pathway 1.781 0.002 0.0449
Cytokine signaling
KEGG JAK STAT signaling pathway 1.977 0.000 0.0119
PID IL12 STAT4 pathway 1.775 0.004 0.0454
Reactome interferon signaling 2.701 0.000 0.0000
Reactome interferon alpha beta signaling 2.760 0.000 0.0000
Reactome interferon gamma signaling 2.303 0.000 0.0000
PID IFNG pathway 1.787 0.002 0.0434
PID SMAD2 3 nuclear pathway 2.094 0.000 0.0031
Reactome transcriptional activity OF SMAD2 SMAD3 SMAD4 heterotrimer 1.794 0.002 0.0421
Reactome SMAD2 SMAD3 SMAD4 heterotrimer regulates transcription 1.771 0.012 0.0451
Differentiation, proliferation and apoptosis
PID notch pathway 1.916 0.000 0.0163
PID Betacatenin Nuc pathway 1.844 0.002 0.0271
Biocarta gleevec pathway 1.862 0.000 0.0237
PID CMYB pathway 1.842 0.000 0.0271
Reactome YAP1 AND WWTR1 TAZ stimulated gene expression 1.804 0.008 0.0400
PID P53 downstream pathway 1.772 0.000 0.0452
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Table 3 Summary of the GSEA-identified gene sets in in vitro activated T cells of psoriasis patients compared to
healthy controls (Continued)
Metabolism
Reactome cholesterol biosynthesis 2.050 0.000 0.0063
Reactome fatty acid triacylglycerol and ketone body metabolism 1.961 0.000 0.0128
Reactome metabolism of lipids and lipoproteins 1.927 0.000 0.0157
KEGG biosynthesis of unsaturated fatty acids 1.790 0.006 0.0429
KEGG glycine serine and threonine metabolism 1.877 0.000 0.0227
KEGG metabolism of xenobiotics by cytochrome P450 1.924 0.002 0.0157
Reactome PPARA activates gene expression 2.076 0.000 0.0043
Biocarta PPARA pathway 1.780 0.006 0.0444
Unfolded protein response
Reactome unfolded protein response 1.972 0.000 0.0120
Reactome perk regulated gene expression 1.872 0.000 0.0230
Reactome activation of genes by ATF4 1.896 0.000 0.0180
PID ATF2 pathway 1.977 0.000 0.0125
Other
KEGG intestinal immune network for IGA production 1.996 0.000 0.0117
KEGG lysosome 1.951 0.000 0.0127
Reactome generic transcription pathway 1.813 0.000 0.0372
PID HIF1 TFPATHWAY 1.778 0.002 0.0444
Reactome RORA activates circadian expression 1.773 0.007 0.0457
List of the enriched gene sets in psoriasis phenotype compared to control phenotype showing a FDR < 0.05. Gene sets are classified according to the processes
where they are involved. Normalized enrichment score (NES), nominal p-value (NOM p-value) and false discovery rate (FDR q-value) are indicated.
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come these limitations by characterizing the differential
gene expression profile of in vitro activated T cells in
psoriasis patients and controls. To our knowledge, it is
the first study to analyze T cell activation in psoriasis
using whole-genome gene expression analysis.
In the microarray analysis of in vitro activated T cells
we were able to identify 42 genes differentially expressed
between psoriasis patients and controls. Using an inde-
pendent sample of patients and controls we validated
the association of the two genes most highly overex-
pressed in psoriasis T cells, SPATS2L and KLF6. It is the
first time that SPATS2L and KLF6 genes have been asso-
ciated with the T cell activation process in psoriasis.
To date, little is known on the biological functionality
of SPATS2L. In our study, combining gene coexpression
network analysis and Gene Ontology enrichment we
found that SPATS2L gene network is associated to pro-
cesses associated with the activation of gene expression
including chromosomal organization and ribosomal bio-
genesis. This potential association of SPATS2L with ribo-
somal processes and translational control has been
previously described in gene-trap experiments con-
ducted in myoblasts under oxidative stress [33]. Riboso-
mal biogenesis has been proved to be critical in the
control of cell growth and cell proliferation [34], and inT cells, is one of the most significantly up-regulated cel-
lular processes during cell-cycle entry [35]. Therefore,
the overexpression of SPATS2L in activated T cells from
psoriasis patients could be contributing to an earlier ac-
tivation of these lymphocytes compared to healthy
controls.
Consistently with this potential role in altered cell acti-
vation, there is evidence that SPATS2L is associated with
lymphoproliferative-type of disorders. Analyzing the
overexpression of SPATS2L in different human diseases,
we found that SPATS2L is one of the genes most signifi-
cantly overexpressed in lymphocytes from patients with
chronic lymphocytic leukemia (CLL) compared to cells
from normal controls (Additional file 8) [36]. Also,
SPATS2L is found to be significantly overexpressed in a
mouse model of T-cell acute lymphoblastic leukemia
(Additional file 8) [37]. Furthermore, gene expression
data from leukemia cell lines treated with anti-leukemic
agent Imatinib, shows a significant downregulation of
SPATS2L (Additional file 8). Finally, a recent genome-
wide association study (GWAS) data on risk loci for
lymphoblastic leukemia has shown a significant associ-
ation of a Single Nucleotide Polymorphism in the
SPATS2L locus [38]. Together, these results show that
SPATS2L functionality is strongly associated with the ab-
errant activation of lymphocytes.
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phoproliferative disorders could share common genetic
basis. Patients with psoriasis have an increased risk of
developing leukemia, in particular lymphoma [39]. In a
GWAS performed in follicular lymphoma, the region
with most significant association was located near the
psoriasis susceptibility region 1 (PSORS1) in chromo-
some 6 [40]. Furthermore, a fairly common manifest-
ation of certain leukemias, including lymphocytic
leukemias, is the infiltration of neoplastic leukocytes in
skin tissue, also known as leukemia cutis [41]. Therefore,
it is tempting to speculate that SPATS2L is involved in a
common genetic pathway associated with psoriasis and
lymphoproliferative-type of disorders. This pathway
would therefore participate in the aberrant lymphocyte
activity observed in both diseases and the preferential in-
filtration of skin tissue by these altered lymphocytes.
KLF6 encodes a member of Kruppel family of tran-
scription factors [42], several of which have been previ-
ously implicated in T lymphocyte biology [43]. KLF6 has
been previously shown to be expressed in lymphoid cells
[44,45] and, similarly to SPATS2L, there is also evidence
of differential expression of KLF6 in T cells from CLL
patients compared to controls [46]. Compared to
SPATS2L however, KLF6 coexpression network showed
a highly significant Gene Ontology enrichment, mainly
in ontologies related to the biosynthesis of lipids and
proteins. These biosynthetic processes are induced in
cells that are stimulated to rapidly grow and proliferate,
as it is the case of activated T cells [47-50]. Two other
significant biological processes enriched in the KLF6 net-
work were endoplasmic reticulum stress and biosyn-
thesis of hydrogen sulfide. These processes are linked to
another process also found to be enriched by psoriasis in
GSEA analysis which is the unfolded protein response
(UPR) [51,52]. Interestingly, the expression of KLF6 and
other KLF members has been previously reported to be
up-regulated when UPR is induced by different drugs,
such as tunicamycin [53] or thapsigargin (Additional file 8)
[54]. On the basis of this information, it is possible that
in T cells from psoriasis patients, KLF6 up-regulation
may also be induced by an UPR, in this case, triggered
by the increase in protein-folding load required upon T
cell activation.
We have investigated the biological processes that take
place during T cell activation associated with psoriasis
using both an unsupervised approach which does not
use sample information, WGCNA, as well as a super-
vised approach, GSEA, which compares gene sets over-
represented in cases compared to controls. Even though
these are clearly different functional analysis, they re-
sulted in the identification of common biological pro-
cesses. One of these common biological processes was
the biosynthesis of lipids and proteins. For example,cholesterol biosynthesis was the most significantly
enriched process in KLF6 coexpression network and was
also detected by GSEA as one of the most enriched pro-
cesses in T cells from psoriasis patients. This enrichment
in genes involved in biosynthetic processes could be at-
tributed to an early activation of T cells from psoriasis
patients. Another common biological pathway identified
in both approaches was the endoplasmic reticulum
stress and unfolded protein response. Interestingly, these
two processes, which may result from the increased
protein-folding load required in activated T cells, have
been associated with a number of chronic inflammatory
and autoimmune diseases like spondyloarthritis, rheuma-
toid arthritis, inflammatory bowel diseases or multiple
sclerosis [55-57].
The most significantly enriched gene sets identified by
GSEA were, however, related to cytokine signalling
(FDR < 0.0001), more specifically, to genes involved in
the interferon signalling pathway (IFN pathway FDR <
0.0001; IFNG signalling, FDR < 0.0001; IFNA/B signal-
ling, FDR < 0.0001). This result is fully consistent with
the strong interferon-signature detected in psoriasis skin
lesions [20]. In line with this observation, GSEA results
also show evidence of an association with IL12-STAT4
pathway, an interferon gamma inducing pathway, al-
though at much lower significance. IFN has been shown
to drive activation and differentiation of IL17 and IL22
producing T cells [58], and to increase keratinocyte re-
sponsiveness to IL22 which leads to the observed hyper-
proliferation [59]. In line with these observations, GSEA
analysis also identified an enrichment of innate immune
sensing mechanisms related to the production of IFN
like RIG-I receptor signaling pathway (FDR = 0.0005)
[60] and the NLR family of receptors like NOD2 [61]
(FDR = 0.0058). Together, these results suggest that IFN
response pathway is more strongly activated in T cells
from psoriasis patients than normal healthy controls.
The four T cell gene networks associated with psoria-
sis risk identified through WGCNA analysis were found
to be highly enriched for genes associated to the re-
sponse to virus biological process (Additional file 9). A
total of 14 genes (BCL2, ISG15, EIF2AK2, IFIH1, IRF7,
ISG20, IFI35, IFI44, MX1, MX2, RSAD2, STAT1, STAT2
and TRIM5) out of 61 overexpressed by T cells (P < 1e-
16, test for enrichment) were associated to the response
to a viral infection. This result is in accordance with the
recent evidence implicating an increased antiviral activ-
ity in psoriatic skin compared to skin from normal con-
trols or patients with atopic dermatitits [62]. In this
model, keratinocytes are rendered hyperresponsive to-
wards an antiviral response after being conditioned from
T helper 17 (Th17) cell-type cytokines.
In the last years the two newly characterized T-cell
subsets, Th17 and Th22, have been increasingly
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approach does not provide direct evidence of an increase
of either cell subset, it describes an increased activation
of precursor cells in affected individuals. It is therefore
likely that this differential activity predisposes to these
two particular cell types once in the skin microenviron-
ment of psoriasis patients. Additional studies will be
needed to confirm this hypothesis. Another limitation of
our study is that we analyzed the global expression
changes of all activated T cells, regardless of the specific
subphenotype. While we found no statistically significant
differences in CD4+ or CD8+ percentages in cases com-
pared to controls (data not shown), it is possible that
specific subphenotypes are differently represented be-
tween the two groups. Therefore, future studies will be
performed to identify which cell subtype/s are respon-
sible for each of the differentially expressed genes and
genetic pathways associated with psoriasis in our study.
Conclusions
In the present study, we have investigated for the first
time the gene expression profile specifically associated
with T cell activation in psoriasis. We have identified
SPATS2L and KLF6 as the two genes most significantly
overexpressed in activated T cells from psoriasis patients
and we have validated this overexpression in an inde-
pendent case-control cohort. Functional analysis of the
gene coexpression networks, suggest that SPATS2L and
KLF6 might be involved in an early activation process.
Global functional enrichment also shows a strong preva-
lence of interferon cytokine mediated signalling in acti-
vated T cells from psoriasis compared to controls. The
results of this study associate new biological pathways
with psoriasis etiology and establish new lines of re-
search that will clearly lead to an improved knowledge
of the biological basis of this disease and, hopefully, to
improved therapies in the near future.
Methods
Subjects
Fifteen healthy controls and twenty-five psoriasis pa-
tients were included in the present study. Controls
(mean ± SD age 40.8 ± 8.8 years; 9 men and 6 women)
didn’t have psoriasis or any other immune mediated in-
flammatory disease and were collected from medical
staff at the Vall d’Hebron Hospital (Barcelona, Spain).
Psoriasis patients (mean ± SD age 46 ± 8.4 years; 14 men
and 11 women), were recruited from the outpatient’s
clinics of the dermatology departments from Santa Creu
i Sant Pau Hospital (Barcelona, Spain) and Germans
Trias i Pujol Hospital (Badalona, Spain). All selected pa-
tients had chronic plaque psoriasis as diagnosed by a
dermatologist, affecting torso and/or extremities with at
least one year of duration. Patients with a single clinicallocalization of plaque psoriasis (i.e. scalp, face, palmo-
plantar), with exclusively inverse plaque psoriasis or with
an inflammatory bowel disease were excluded. All pa-
tients were >18 years old at the time of recruitment, al-
though disease onset could have occurred at an earlier
age.
Informed consent was obtained from all participants
and protocols were reviewed and approved by the Vall
d’Hebron University Hospital ethics committee. The
present study was conducted according to the Declar-
ation of Helsinki principles. Additional file 1 summarizes
the main clinical features of patients and controls (age,
gender, PASI score).
Cell culture
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from whole blood of patients and controls by cen-
trifugation on a Ficoll-Paque PLUS (GE Healthcare
Biosciences AB, Uppsala, Sweden) density gradient.
PBMCs were then seeded in complete RPMI 1640
medium supplemented with 100 U/ml penicillin, 100 U/ml
streptomycin, 10% fetal bovine serum, 2 mM L-glutamine
and 50 μM mercaptoethanol, and activated with 1μg/ml
of anti-CD3 and anti-CD28 antibodies (eBioscience,
San Diego, CA, USA). After 72 hours of stimulation,
activated T cells were harvested by centrifugation and
processed for flow cytometry study or frozen at -20°C
for subsequent RNA isolation.
Flow cytometry analysis
In order to characterize the T lymphocyte population
present in cultured PBMCs samples and verify their acti-
vation after stimulation by CD3 and CD28 ligation, we
performed flow cytometric analysis. In vitro activated cells
were stained with anti-human CD4-PE (eBioscience, San
Diego, CA, USA) and anti-human CD8-PerCP (Biolegend,
San Diego, CA, USA) antibodies before acquisition
(FC500 Flow Cytometer, Beckman Coulter, CA, USA) and
analysis (Flowjo, Tree Star, Inc., Oregon, USA). Forward
and side scatters were used to gate resting and blast lym-
phocytes, and CD4+ or CD8+ -type cells were counted
within each gate. The average percentage of blasting cells
was 75.94 (+/- 9.9) with 51.36% (+/-11.3) being CD4+ and
37.87% (+/-10.7) corresponding to CD8+. No statistically
significant differences were observed between cases and
controls.
RNA isolation
Total RNA was isolated from previously activated T cells
using the RNeasy mini kit (Qiagen, Hilden, Germany).
RNA yield was assessed using a NanoDrop 1000 spec-
trophotometer (Thermo Fisher Scientific, USA) and
RNA integrity was assessed using the RNA 6000 Nano
LabChip Kit on an Agilent 2100 Bioanalyser (Agilent
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had a RNA Integrity Number higher than 9 and were
subsequently used for microarray analysis.
Microarray analysis and differential gene expression
determination
Whole genome gene expression analysis of in vitro acti-
vated T cells for 17 psoriasis patients and 7 healthy con-
trols was carried out by the HudsonAlpha Institute for
Biotechnology using the Illumina HT-12 V4 microarrays
(Illumina, USA). Briefly, the Illumina CustomPrep RNA
amplification kit (Appiled Biosystems, USA) was used to
generate biotinylated amplified complementary RNA
(cRNA) from 200 ng of the extracted total RNA. Labelled
cRNA was then hybridized overnight to the Illumina mi-
croarrays, washed, blocked, stained and scanned using the
Illumina BeadStation 500. The GenomeStudio software
v2011.1 (Illumina, USA) was used to generate the raw data
from the microarray scanned images. HT-12 V4 microar-
rays allow the simultaneous profiling of >47,000 tran-
scripts, which include 28,688 well-established RefSeq
annotations from the Human RefSeq (Rel 38). Sample la-
beling, microarray hybridization, scanning and raw data
acquisition were performed at HudsohAlpha Institute for
Biotechnology (Alabama, USA).
Data preprocessing, normalization and differential ex-
pression was performed using the R-statistical software
v12.0 [63]. Log2-transformed data was normalized using
the quantile normalization method [64]. Using the probe
detection p-value calculated by GenomeStudio, only
those transcripts present in 3 or more samples were
considered for differential expression analysis. After fil-
tering, a total of 25,539 transcripts were finally used to
determine the associated gene expression profiles. Dif-
ferential gene expression between cases and controls
was tested using the t-test method implemented in the
Bioconductor multtest package [65]. Correction for mul-
tiple testing was performed using the Benjamini and
Hochberg False Discovery Rate method [66]. From these
significant genes, only those having an absolute fold
change >1.2 were considered to be differentially
expressed between the two conditions.
Real-time PCR validation
200 ng of total RNA from 8 psoriasis cases and 8 con-
trols were reverse-transcribed using the High Capacity
cDNA Reverse Transcription Kit (Invitrogen, Carlsbad,
CA) following the manufacturer’s instructions. Real-time
PCRs were performed on an ABI PRISM7900 Sequence
Detection HT system (Applied Biosystems, Foster City,
CA, USA) and using the TaqMan® chemistry (Applied
Biosystems, Foster City, CA, USA). The thermal cycle
conditions were: 50°C for two minutes, 95°C for 10 mi-
nutes and 40 cycles of 95°C for 15 seconds and 60°C forone minute. The selected TaqMan expression assays
were: Hs01016366_m1 (SPATS2), Hs00296661_s1 (KLF6),
Hs00916867_m1 (SP140), Hs00931153_m1 (RORA) and
Hs01060665_g1 (ACTB). The method of 2 - [Delta]
[Delta] Ct was used to obtain the mRNA expression of
psoriasis samples relative to the control samples, normal-
izing the Ct values of target genes with those of the house-
keeping gene actin beta (ACTB).
Gene expression network analysis
Genes involved in a same biological process or genetic
pathway tend to show correlated levels of expression.
Using this property there are different methods that are
able to build up networks of genes that better
characterize the biological process of interest [67]. Such
analysis can also provide a powerful approach for eluci-
dating the unknown role of a given gene, based on the
pathways or processes in which the other genes in the
same network are involved. In the present study we have
used the Weighted correlation network analysis (WGCNA)
approach to infer the gene expression modules in acti-
vated T cells that are associated with psoriasis [28]. After
calculating the co-expression matrix using Pearson’s cor-
relation method, a network adjacency is calculated by rais-
ing the co-expression similarity to a power β. Then using
the scale-free topology criterion [68], the threshold par-
ameter that defines the connectivity between genes is
chosen. Once the threshold for connectivity is set, the
coexpression network can be built. Within this network,
clusters of densely connected genes (i.e. modules) are de-
fined using unsupervised clustering and the Dynamic Tree
Cut method [69]. Finally, for each gene expression module
a summary measure or eigengene can be calculated using
the first principal component of the corresponding ex-
pression matrix. Each eigengene was subsequently used to
test for association with psoriasis and other relevant clin-
ical and epidemiological covariates (age, gender, PASI
score, % of activated lymphocytes and % CD4 or CD8
subsets). For binary variables the t-test was used, while
for quantitative variables a linear regression approach
was used.
In order to contextualize the gene networks associated
with psoriasis, we performed a comprehensive search for
previous studies having found evidence between the net-
work genes and the disease. Using each gene annotation
and the term ‘psoriasis’ we performed systematic queries
using NCBI Pubmed database (October 2013). In order to
reduce the presence of false positives only genes with ab-
solute FCH > 1.2 were included. A total of 70 overex-
pressed genes and 22 underexpressed genes were queried.
Functional annotation of expression modules
Gene Ontology (GO) category enrichment analysis was
performed using DAVID online tool (i.e. Database for
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http://david.abcc.ncifcrf.gov/, Bethesda, MD, USA) [29].
Briefly, GO enrichment is calculated comparing the fre-
quency of genes from each different GO present in the
set of differently expressed genes to the frequency of
genes for this same GO in the human genome
background.
Gene set enrichment analysis
GSEA is a software method to analyze and interpret
microarray data using biological knowledge [30,31].
Using the differential gene expression result between
cases and controls and a list of predefined biological sets
of genes, GSEA tests the overrepresentation each gene
set in the group of most associated genes compared to
the group of genes showing lower –or none- evidence of
association. In the present study we used GSEA version
2.0.12 (www Broad Institute at MIT), with the C2 cu-
rated canonical pathway gene set (i.e. c2.cp.v3.1.symbols.
gmt download), collapsing of dataset to gene symbols,
weighted enrichment statistic and real gene list sorting.
Maximum size of gene sets was set to 500 genes and
minimum gene set size was set to 15. Empirical signifi-
cance values were calculated using 10,000 permutations.
Availability of supporting data
The datasets supporting the results of this article are
available in NCBI’s gene Expression Omnibus and are




Additional file 1: Data on the subjects included in the study. List of
subjects included in the microarray and validation studies with
information relative to their gender, age and PASI score. M, male;
F, female; PASI, Psoriasis Area Severity Index.
Additional file 2: Differentially expressed genes in in vitro activated
T cells. Complete list of genes with a Benjamini and Hochberg corrected
p-value < 0.1 and absolute FCH > 1.2. Genes are classified in up-regulated
or down-regulated and sorted by their statistical significance.
Additional file 3: Gene coexpression networks in in vitro activated
T cells. 20 gene coexpression modules that resulted from weighted
correlation network analysis applied to the complete microarray samples.
Additional file 4: Association results of the gene coexpression
modules with different clinical and epidemiological variables. For
binary variables the t-test was used, while for quantitative variables a
linear regression approach was used. Significant p-values (P < 0.05) are
highlighted in bold.
Additional file 5: Visualization of the gene modules associated with
psoriasis. Using a heatmap plot we can visualize the level of adjacency
of the genes that conform the four gene expression networks associated
with psoriasis (light colors indicate low adjacency, dark colors high
adjacency). Each module is depicted by a different color: M1 (grey), M2
(green), M3 (blue) and M4 (pink).
Additional file 6: Visualization of the eigengene network with each
clinical variable. Using a heatmap plot we can visualize the relationshipsamong the modules (representetd by their eigengenes) and each of the
clinical traits. The level of correlation is a scale that goes from 0 (green)
to 1 (red). Each module is depicted by a different color: grey (M1),
greenyellow (M2), royalblue (M3), pink (M4), black (M5), blue (M6), brown
(M7), cyan (M8), green (M9), lightcyan (M10), lightgreen (M11), lightyellow
(M12), magenta (M13), midnightblue (M14), purple (M15), red (M16),
salmon (M17), tan (M18), turquoise (M19), yellow (M20).
Additional file 7: Summary of enriched GO terms in SPATS2L and
KLF6 coexpression networks. List of enriched GO terms related to
biological process, cellular component and molecular function in the
SPATS2L and KLF6 coexpression networks. For each term, the number of
genes present in the network (count), the percentage of enrichment (%),
the associated p-value and the genes present in the network are
indicated.
Additional file 8: List of GEO profiles showing highly significant
differential expression of SPATS2L and KLF6 genes. Selection of
SPATS2L and KLF6 GEO profiles showing highly significant differential
expression. For each GEO profile, the accession number, the title and a
description of their corresponding GEO DataSets are provided.
Additional file 9: List of PubMed articles on genes from the T cell
gene networks associated with psoriasis risk.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiment: NP, AJ, CF, LP, SM. Performed the
experiments: NP, CF, LP, RT. Analyzed the data: AJ, NP. Provided material: CF,
LP, EFo, EFe, MLL. Wrote the manuscript: NP, CF, LP, RT, AJ, SM. All authors
read and approved the manuscript.
Acknowledgements
We thank Devin Absher and the HudsonAlpha Institute for Biotechnology for
their support. We thank Natalia Figueras Sanchez for technical assistance.
This study was funded by of the Spanish Ministry of Economy and
Competitiveness, grant numbers: PSE-010000-2006-6 and IPT-010000-2010-36.
The study sponsor had no role in the collection, analysis or interpretation of
the data.
Author details
1Rheumatology Research Group, Vall d’Hebron Research Institute, Barcelona
08035, Spain. 2Dermatology Service, Hospital Universitari Germans Trias i
Pujol, Badalona 08916, Spain. 3Dermatology Service, Hospital de la Santa
Creu i Sant Pau, Barcelona 08040, Spain. 4Dermatology Service, Hospital
Abente y Lago, La Coruña 15001, Spain. 5Dermatology Service, Hospital
Universitario de Salamanca, Salamanca 37007, Spain.
Received: 17 June 2013 Accepted: 19 November 2013
Published: 23 November 2013
References
1. Enamandram M, Kimball AB: Psoriasis epidemiology: the interplay of
genes and the environment. J Invest Dermatol 2013, 133(2):287–289.
2. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM: CD69, HLA-DR and
the IL-2R identify persistently activated T cells in psoriasis vulgaris
lesional skin: blood and skin comparisons by flow cytometry.
J Autoimmun 2000, 14(1):63–78.
3. Griffiths CE, Barker JN: Pathogenesis and clinical features of psoriasis.
Lancet 2007, 370(9583):263–271.
4. Mueller W, Herrmann B: Cyclosporin A for psoriasis. N Engl J Med 1979,
301(10):555.
5. Wrone-Smith T, Nickoloff BJ: Dermal injection of immunocytes induces
psoriasis. J Clin Invest 1996, 98(8):1878–1887.
6. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, Lebwohl MG,
Guzzo CA, Jegasothy BV, Linsley PS, et al: Blockade of T lymphocyte
costimulation with cytotoxic T lymphocyte-associated antigen
4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic
plaques, including the activation of keratinocytes, dendritic cells, and
endothelial cells. J Exp Med 2000, 192(5):681–694.
Palau et al. BMC Genomics 2013, 14:825 Page 12 of 13
http://www.biomedcentral.com/1471-2164/14/8257. Gottlieb AB, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G, Solodkina
G, Grossman R, Gisoldi E, Phillips S, et al: Anti-CD4 monoclonal antibody
treatment of moderate to severe psoriasis vulgaris: results of a pilot,
multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol
2000, 43(4):595–604.
8. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB,
Krueger JG: Response of psoriasis to a lymphocyte-selective toxin
(DAB389IL-2) suggests a primary immune, but not keratinocyte,
pathogenic basis. Nat Med 1995, 1(5):442–447.
9. Nickoloff BJ: Skin innate immune system in psoriasis: friend or foe? J Clin
Invest 1999, 104(9):1161–1164.
10. Prinz J, Braun-Falco O, Meurer M, Daddona P, Reiter C, Rieber P, Riethmuller
G: Chimaeric CD4 monoclonal antibody in treatment of generalised
pustular psoriasis. Lancet 1991, 338(8762):320–321.
11. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ: The cytokine
network in lesional and lesion-free psoriatic skin is characterized by a
T-helper type 1 cell-mediated response. J Invest Dermatol 1993, 101(5):701–705.
12. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F: Production of
interleukin 22 but not interleukin 17 by a subset of human skin-homing
memory T cells. Nat Immunol 2009, 10(8):857–863.
13. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS,
Bowman EP, Krueger JG: Psoriasis vulgaris lesions contain discrete
populations of Th1 and Th17 T cells. J Invest Dermatol 2008, 128(5):1207–1211.
14. Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, Dunussi-
Joannopoulos K, Fouser LA, Renauld JC, Dumoutier L: IL-22 is required for
imiquimod-induced psoriasiform skin inflammation in mice. J Immunol
2012, 188(1):462–469.
15. Bigler J, Rand HA, Kerkof K, Timour M, Russell CB: Cross-study homogeneity
of psoriasis gene expression in skin across a large expression range. PLoS
One 2013, 8(1):e52242.
16. Bowcock AM, Shannon W, Du F, Duncan J, Cao K, Aftergut K, Catier J,
Fernandez-Vina MA, Menter A: Insights into psoriasis and other inflammatory
diseases from large-scale gene expression studies. Hum Mol Genet 2001,
10(17):1793–1805.
17. Coda AB, Icen M, Smith JR, Sinha AA: Global transcriptional analysis of
psoriatic skin and blood confirms known disease-associated pathways
and highlights novel genomic “hot spots” for differentially expressed
genes. Genomics 2012, 100(1):18–26.
18. Gudjonsson JE, Ding J, Johnston A, Tejasvi T, Guzman AM, Nair RP, Voorhees
JJ, Abecasis GR, Elder JT: Assessment of the psoriatic transcriptome in a
large sample: additional regulated genes and comparisons with in vitro
models. J Invest Dermatol 2010, 130(7):1829–1840.
19. Oestreicher JL, Walters IB, Kikuchi T, Gilleaudeau P, Surette J, Schwertschlag
U, Dorner AJ, Krueger JG, Trepicchio WL: Molecular classification of
psoriasis disease-associated genes through pharmacogenomic expression
profiling. Pharmacogenomics J 2001, 1(4):272–287.
20. Yao Y, Richman L, Morehouse C, de los Reyes M, Higgs BW, Boutrin A, White
B, Coyle A, Krueger J, Kiener PA, et al: Type I interferon: potential
therapeutic target for psoriasis? PLoS One 2008, 3(7):e2737.
21. Zhou A, Scoggin S, Gaynor RB, Williams NS: Identification of NF-kappa
B-regulated genes induced by TNFalpha utilizing expression profiling
and RNA interference. Oncogene 2003, 22(13):2054–2064.
22. Jung M, Sabat R, Kratzschmar J, Seidel H, Wolk K, Schonbein C, Schutt S, Friedrich
M, Docke WD, Asadullah K, et al: Expression profiling of IL-10-regulated genes
in human monocytes and peripheral blood mononuclear cells from psoriatic
patients during IL-10 therapy. Eur J Immunol 2004, 34(2):481–493.
23. Koczan D, Guthke R, Thiesen HJ, Ibrahim SM, Kundt G, Krentz H, Gross G,
Kunz M: Gene expression profiling of peripheral blood mononuclear
leukocytes from psoriasis patients identifies new immune regulatory
molecules. Eur J Dermatol 2005, 15(4):251–257.
24. Lee SK, Jeon EK, Kim YJ, Seo SH, Kim CD, Lim JS, Lee JH: A global gene
expression analysis of the peripheral blood mononuclear cells reveals the
gene expression signature in psoriasis. Ann Dermatol 2009, 21(3):237–242.
25. Mesko B, Poliska S, Nagy L: Gene expression profiles in peripheral blood for
the diagnosis of autoimmune diseases. Trends Mol Med 2011, 17(4):223–233.
26. Cotner T, Williams JM, Christenson L, Shapiro HM, Strom TB, Strominger J:
Simultaneous flow cytometric analysis of human T cell activation
antigen expression and DNA content. J Exp Med 1983, 157(2):461–472.
27. Feng X, Wang H, Takata H, Day TJ, Willen J, Hu H: Transcription factor
Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive
T cells. Nat Immunol 2011, 12(6):544–550.28. Langfelder P, Horvath S: WGCNA: an R package for weighted correlation
network analysis. BMC Bioinforma 2008, 9:559.
29. da Huang W, Sherman BT, Lempicki RA: Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat
Protoc 2009, 4(1):44–57.
30. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al: Gene set enrichment
analysis: a knowledge-based approach for interpreting genome-wide
expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545–15550.
31. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J,
Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al: PGC-1alpha-
responsive genes involved in oxidative phosphorylation are coordinately
downregulated in human diabetes. Nat Genet 2003, 34(3):267–273.
32. Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, de Bono B, Garapati
P, Hemish J, Hermjakob H, Jassal B, et al: Reactome knowledgebase of
human biological pathways and processes. Nucleic Acids Res 2009,
37(Database issue):D619–D622.
33. Zhu CH, Kim J, Shay JW, Wright WE: SGNP: an essential Stress Granule/
Nucleolar Protein potentially involved in 5.8s rRNA processing/transport.
PLoS One 2008, 3(11):e3716.
34. Donati G, Montanaro L, Derenzini M: Ribosome biogenesis and control of
cell proliferation: p53 is not alone. Cancer Res 2012, 72(7):1602–1607.
35. Orr SJ, Boutz DR, Wang R, Chronis C, Lea NC, Thayaparan T, Hamilton E,
Milewicz H, Blanc E, Mufti GJ, et al: Proteomic and protein interaction
network analysis of human T lymphocytes during cell-cycle entry. Mol
Syst Biol 2012, 8:573.
36. Gutierrez A Jr, Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, Huddleston PM
3rd, Slager SL, Kay NE, Jelinek DF: LEF-1 is a prosurvival factor in chronic
lymphocytic leukemia and is expressed in the preleukemic state of
monoclonal B-cell lymphocytosis. Blood 2010, 116(16):2975–2983.
37. Jeannet R, Mastio J, Macias-Garcia A, Oravecz A, Ashworth T, Geimer Le Lay
AS, Jost B, Le Gras S, Ghysdael J, Gridley T, et al: Oncogenic activation of
the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL.
Blood 2010, 116(25):5443–5454.
38. Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y, Pounds SB, Neale G, Trevino
LR, French D, et al: Genome-wide interrogation of germline genetic
variation associated with treatment response in childhood acute
lymphoblastic leukemia. Jama 2009, 301(4):393–403.
39. Brauchli YB, Jick SS, Miret M, Meier CR: Psoriasis and risk of incident
cancer: an inception cohort study with a nested case-control analysis.
J Invest Dermatol 2009, 129(11):2604–2612.
40. Skibola CF, Bracci PM, Halperin E, Conde L, Craig DW, Agana L, Iyadurai K,
Becker N, Brooks-Wilson A, Curry JD, et al: Genetic variants at 6p21.33 are
associated with susceptibility to follicular lymphoma. Nat Genet 2009,
41(8):873–875.
41. Cho-Vega JH, Medeiros LJ, Prieto VG, Vega F: Leukemia cutis. Am J Clin
Pathol 2008, 129(1):130–142.
42. Andreoli V, Gehrau RC, Bocco JL: Biology of Kruppel-like factor 6 transcriptional
regulator in cell life and death. IUBMB Life 2010, 62(12):896–905.
43. Cao Z, Sun X, Icli B, Wara AK, Feinberg MW: Role of Kruppel-like factors in
leukocyte development, function, and disease. Blood 2010, 116(22):4404–4414.
44. Yang XO, Doty RT, Hicks JS, Willerford DM: Regulation of T-cell receptor D
beta 1 promoter by KLF5 through reiterated GC-rich motifs. Blood 2003,
101(11):4492–4499.
45. Warke VG, Nambiar MP, Krishnan S, Tenbrock K, Geller DA, Koritschoner NP,
Atkins JL, Farber DL, Tsokos GC: Transcriptional activation of the human
inducible nitric-oxide synthase promoter by Kruppel-like factor 6. J Biol
Chem 2003, 278(17):14812–14819.
46. Kiaii S, Kokhaei P, Mozaffari F, Rossmann E, Pak F, Moshfegh A, Palma M,
Hansson L, Mashayekhi K, Hojjat-Farsangi M, et al: T cells from indolent CLL
patients prevent apoptosis of leukemic B cells in vitro and have altered
gene expression profile. Cancer Immunol Immunother 2013, 62(1):51–63.
47. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA,
Shih R, Parks JS, Edwards PA, Jamieson BD, et al: LXR signaling couples
sterol metabolism to proliferation in the acquired immune response. Cell
2008, 134(1):97–111.
48. Bensinger SJ, Tontonoz P: Integration of metabolism and inflammation by
lipid-activated nuclear receptors. Nature 2008, 454(7203):470–477.
49. Marelli-Berg FM, Fu H, Mauro C: Molecular mechanisms of metabolic
reprogramming in proliferating cells: implications for T-cell-mediated
immunity. Immunology 2012, 136(4):363–369.
Palau et al. BMC Genomics 2013, 14:825 Page 13 of 13
http://www.biomedcentral.com/1471-2164/14/82550. Pearce EL: Metabolism in T cell activation and differentiation. Curr Opin
Immunol 2010, 22(3):314–320.
51. Krishnan N, Fu C, Pappin DJ, Tonks NK: H2S-Induced sulfhydration of the
phosphatase PTP1B and its role in the endoplasmic reticulum stress
response. Sci Signal 2011, 4(203):ra86.
52. Miller TW, Wang EA, Gould S, Stein EV, Kaur S, Lim L, Amarnath S, Fowler
DH, Roberts DD: Hydrogen sulfide is an endogenous potentiator of T cell
activation. J Biol Chem 2012, 287(6):4211–4221.
53. Mungrue IN, Pagnon J, Kohannim O, Gargalovic PS, Lusis AJ: CHAC1/
MGC4504 is a novel proapoptotic component of the unfolded protein
response, downstream of the ATF4-ATF3-CHOP cascade. J Immunol 2009,
182(1):466–476.
54. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO,
Yandell M, Evans CA, Holt RA, et al: The sequence of the human genome.
Science 2001, 291(5507):1304–1351.
55. Chakrabarti A, Chen AW, Varner JD: A review of the mammalian unfolded
protein response. Biotechnol Bioeng 2011, 108(12):2777–2793.
56. Hasnain SZ, Lourie R, Das I, Chen AC, McGuckin MA: The interplay between
endoplasmic reticulum stress and inflammation. Immunol Cell Biol 2012,
90(3):260–270.
57. Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM: Lighting the fires
within: the cell biology of autoinflammatory diseases. Nat Rev Immunol
2012, 12(8):570–580.
58. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, Burg G,
Liu YJ, Gilliet M: Plasmacytoid predendritic cells initiate psoriasis through
interferon-alpha production. J Exp Med 2005, 202(1):135–143.
59. Tohyama M, Yang L, Hanakawa Y, Dai X, Shirakata Y, Sayama K: IFN-alpha
enhances IL-22 receptor expression in keratinocytes: a possible role in
the development of psoriasis. J Invest Dermatol 2012, 132(7):1933–1935.
60. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M,
Taira K, Akira S, Fujita T: The RNA helicase RIG-I has an essential function
in double-stranded RNA-induced innate antiviral responses. Nat Immunol
2004, 5(7):730–737.
61. Shaw MH, Reimer T, Sanchez-Valdepenas C, Warner N, Kim YG, Fresno M,
Nunez G: T cell-intrinsic role of Nod2 in promoting type 1 immunity to
Toxoplasma gondii. Nat Immunol 2009, 10(12):1267–1274.
62. Wolk K, Witte K, Witte E, Raftery M, Kokolakis G, Philipp S, Schonrich G,
Warszawska K, Kirsch S, Prosch S, et al: IL-29 Is Produced by TH17 Cells
and Mediates the Cutaneous Antiviral Competence in Psoriasis. Sci Transl
Med 2013, 5(204):204ra129.
63. Team RDC: R: A Language and Environment for Statistical Computing. Vienna:
R Foundation for Statistical Computing; 2009.
64. Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of
normalization methods for high density oligonucleotide array data
based on variance and bias. Bioinformatics 2003, 19(2):185–193.
65. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B,
Gautier L, Ge Y, Gentry J, et al: Bioconductor: open software development for
computational biology and bioinformatics. Genome Biol 2004, 5(10):R80.
66. Benjamini YHM: Controlling the false discovery rate: a practical and
powerful approach to multiple testing. J R Stat Soc 1995, 57(1):289–300.
67. Allen JD, Xie Y, Chen M, Girard L, Xiao G: Comparing statistical methods
for constructing large scale gene networks. PLoS One 2012, 7(1):e29348.
68. Zhang B, Horvath S: A general framework for weighted gene co-
expression network analysis. Stat Appl Genet Mol Biol 2005, 4(1):1544–6115.
69. Langfelder P, Zhang B, Horvath S: Defining clusters from a hierarchical
cluster tree: the Dynamic Tree Cut package for R. Bioinformatics 2008,
24(5):719–720.
doi:10.1186/1471-2164-14-825
Cite this article as: Palau et al.: Genome-wide transcriptional analysis of
T cell activation reveals differential gene expression associated with
psoriasis. BMC Genomics 2013 14:825.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
